Our Ophthalmology Integrated Evaluation Platform focuses on ophthalmic drug use, integrating six major disciplines including toxicology, pharmacodynamics, pathology, ophthalmology, molecular biology, pharmacokinetics, etc., and realizing a specialized platform for the evaluation of “efficacy-pharmacogenetics-toxicity”, with laboratories certified by GLP, FDA, OECD and other certificates, and with data supporting the filing requirements of China, the United States, Europe and many other countries. The platform provides a variety of ophthalmic models, including conjunctival disease, dry eye, keratoconus, uveitis, fundopathy, cataract, glaucoma and myopia. It also has a variety of precision delivery technologies, such as vitreous cavity injection and subretinal injection. We have strong cross-species translational research capabilities, ranging from mice to rabbits to non-human primates, and can provide highly predictive models for preclinical studies. Service categories include gene therapy, mini-nucleic acids, dual-antibodies, small-analyte chemotherapeutics, stem cells, and so on.